ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients

Phase 2

Completed

Conditions: Chronic Hepatitis C
Hepatitis C Genotype 1
Hepatitis C (HCV)

Interventions: Drug: ABT-450
Drug: ABT-267
Drug: ABT-333
Drug: Ribavirin
Drug: Ritonavir

Registration Number: NCT01464827

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Brief Summary: This is a study of combination direct-acting antiviral agents (DAA) with or without ribavirin (RBV) in patients with chronic Hepatitis C Virus (HCV).

Detailed Description: A study to evaluate the safety and effectiveness of experimental drugs ABT-450, ABT-267 (also known as ombitasvir), ABT-333 (also known as dasabuvir), ritonavir, and ribavirin in participants with HCV. The study will test the safety and effects of combinations of these drugs in treatments up to 24 weeks.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 580

Inclusion Criteria

Males and females 18-70 years old, inclusive
Females must be post-menopausal for more than 2 years or surgically sterile or practicing specific forms of birth control
Chronic hepatitis C virus (HCV), genotype 1 infection
Treatment-naive OR null-responders to previous treatment with pegylated interferon (pegIFN) and ribavirin (at least 12 weeks of treatment and failure to achieve a 2 log10 HCV RNA decrease at Week 12)
No evidence of liver cirrhosis

Exclusion Criteria

Significant liver disease with any cause other than HCV as the primary cause
Positive hepatitis B surface antigen and anti-human immunodeficiency virus antibody
Positive screen for drugs and alcohol
Significant sensitivity to any drug
Use of contraindicated or prohibited medications within 1 month of dosing
Abnormal laboratory tests

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group A	ABT-450	Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 8 weeks.
Group C	ABT-267	Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily for 12 weeks.
Group A	ABT-267	Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 8 weeks.
Group B	ABT-450	Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 12 weeks.
Group D	ABT-267	Treatment-naïve participants received ABT-450 200 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily for 12 weeks.
Group B	ABT-333	Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 12 weeks.
Group E	ABT-267	Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ABT-333 400 mg twice daily for 12 weeks.
Group I	ABT-450	Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
Group D	Ribavirin	Treatment-naïve participants received ABT-450 200 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily for 12 weeks.
Group F	ABT-333	Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 12 weeks.
Group F	Ribavirin	Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 12 weeks.
Group H	ABT-267	Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
Group F	Ritonavir	Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 12 weeks.
Group G	ABT-450	Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
Group G	ABT-267	Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
Group I	ABT-267	Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
Group L	ABT-267	Participants who were null-responders to previous HCV treatment received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
Group K	ABT-267	Participants who were null-responders to previous HCV treatment received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
Group M	ABT-267	Participants who were null-responders to previous HCV treatment received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
Group E	ABT-450	Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ABT-333 400 mg twice daily for 12 weeks.
Group F	ABT-450	Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 12 weeks.
Group G	ABT-333	Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
Group H	ABT-333	Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
Group A	ABT-333	Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 8 weeks.
Group C	ABT-450	Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily for 12 weeks.
Group D	ABT-450	Treatment-naïve participants received ABT-450 200 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily for 12 weeks.
Group I	ABT-333	Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
Group E	ABT-333	Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ABT-333 400 mg twice daily for 12 weeks.
Group J	ABT-450	Participants who were null-responders to previous HCV treatment received ABT-450 200 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
Group H	ABT-450	Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
Group K	ABT-333	Participants who were null-responders to previous HCV treatment received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
Group L	ABT-450	Participants who were null-responders to previous HCV treatment received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
Group M	ABT-450	Participants who were null-responders to previous HCV treatment received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
Group K	ABT-450	Participants who were null-responders to previous HCV treatment received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
Group N	ABT-450	Participants who were null-responders to previous HCV treatment received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
Group L	ABT-333	Participants who were null-responders to previous HCV treatment received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
Group M	ABT-333	Participants who were null-responders to previous HCV treatment received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
Group N	ABT-333	Participants who were null-responders to previous HCV treatment received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
Group F	ABT-267	Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 12 weeks.
Group J	ABT-267	Participants who were null-responders to previous HCV treatment received ABT-450 200 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
Group N	ABT-267	Participants who were null-responders to previous HCV treatment received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
Group C	Ribavirin	Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily for 12 weeks.
Group A	Ribavirin	Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 8 weeks.
Group A	Ritonavir	Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 8 weeks.
Group B	Ritonavir	Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 12 weeks.
Group B	Ribavirin	Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 12 weeks.
Group C	Ritonavir	Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily for 12 weeks.
Group D	Ritonavir	Treatment-naïve participants received ABT-450 200 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily for 12 weeks.
Group E	Ritonavir	Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ABT-333 400 mg twice daily for 12 weeks.
Group G	Ribavirin	Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
Group G	Ritonavir	Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
Group H	Ribavirin	Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
Group H	Ritonavir	Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
Group I	Ribavirin	Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
Group I	Ritonavir	Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
Group J	Ritonavir	Participants who were null-responders to previous HCV treatment received ABT-450 200 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
Group J	Ribavirin	Participants who were null-responders to previous HCV treatment received ABT-450 200 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
Group K	Ritonavir	Participants who were null-responders to previous HCV treatment received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
Group K	Ribavirin	Participants who were null-responders to previous HCV treatment received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
Group L	Ribavirin	Participants who were null-responders to previous HCV treatment received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
Group L	Ritonavir	Participants who were null-responders to previous HCV treatment received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
Group M	Ritonavir	Participants who were null-responders to previous HCV treatment received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
Group M	Ribavirin	Participants who were null-responders to previous HCV treatment received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
Group N	Ribavirin	Participants who were null-responders to previous HCV treatment received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
Group N	Ritonavir	Participants who were null-responders to previous HCV treatment received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.

Primary Outcome Measures

Name	Time	Method
Number of Participants With Adverse Events (AEs)	From the time of study drug administration until 30 days following discontinuation of study drug administration (up to 28 weeks).	An adverse event was defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that did not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each AE to the use of direct-acting antiviral agents (DAAs) and to ribavirin, and rated the severity of each event as either: Mild: The AE was transient and easily tolerated by the participant; Moderate: The AE caused the participant discomfort and interrupted usual activities; Severe: The AE caused considerable interference with the participant's usual activities and could have been incapacitating or life-threatening. A serious adverse event was any event that resulted in death, was life-threatening, resulted in or prolonged hospitalization, resulted in a congenital anomaly or persistent or significant disability or was any other important medical event requiring medical or surgical intervention.
Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose for 8 Weeks Versus 12 Weeks of Treatment With 3 DAAs and Ribavirin	Post Treatment Week 24	The percentage of participants achieving sustained virologic response 24 weeks after the last dose of study drug (SVR24), defined as hepatitis C virus (HCV) ribonucleic acid (RNA) less than the lower limit of quantitation (LLOQ), without any confirmed quantifiable (≥ LLOQ) post-treatment value before that time point. HCV RNA levels were measured from plasma by a central laboratory. The LLOQ for the assay was 25 IU/mL. The primary efficacy endpoint was the comparison between treatment-naïve participants following 8 weeks of treatment with 3 DAAs and ribavirin and those with 12 weeks of treatment with 3 DAAs and ribavirin (Group A versus Group G).

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose Following Treatment of Different Durations With 3 Direct-acting Antiviral Agents (DAAs) and Ribavirin	Post-Treatment Week 24	This outcome measure compares the percentage of participants achieving sustained virologic response 24 weeks after the last dose of study drug (HCV RNA \< LLOQ at post-treatment Week 24) following treatment with 3 DAAs (ABT-450/ritonavir, ABT-267, and ABT-333) and ribavirin in both treatment naïve and null-responder participants for 8 weeks (Group A) versus 12 weeks (Groups F + G + K + L) versus 24 weeks (Groups H + I + M + N).
Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose Following Treatment for 12 Weeks With 2 DAAs and Ribavirin Versus 3 DAAs and Ribavirin	Post-Treatment Week 24	This outcome measure compares the percentage of participants achieving sustained virologic response 24 weeks post-dose (HCV RNA \< LLOQ at post-treatment Week 24) following treatment with 2 DAAs (ABT-450/ritonavir plus ABT-333 \[Group B\] or ABT-450/ritonavir plus ABT-267 \[Groups C + D + J\]) and ribavirin versus 3 DAAs (ABT-450/ritonavir plus ABT-333 and ABT-267) and ribavirin (Groups F + G + K + L).
Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose Following Treatment for 12 Weeks With 3 DAAs With Versus Without Ribavirin	Post-Treatment Week 24	This outcome measure compares the percentage of participants achieving sustained virologic response 24 weeks post-dose (HCV RNA \< LLOQ at post-treatment Week 24) following treatment with 3 DAAs with or without ribavirin (Group E versus Groups F + G + K + L).
Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose in Treatment-naïve Versus Null-responders	Post-Treatment Week 24	This outcome measure compares the percentage of participants achieving sustained virologic response 24 weeks post-dose (HCV RNA \< LLOQ at post-treatment Week 24) following treatment with 3 DAAs and ribavirin in participants who were treatment-naïve versus those who were null-responders to previous HCV therapy (Groups F + G + H + I versus Groups K + L + M + N).

Trial Locations

Locations (97): Site Reference ID/Investigator# 55527
🇺🇸
Marietta, Georgia, United States
Site Reference ID/Investigator# 43661
🇺🇸
Jackson, Mississippi, United States
Site Reference ID/Investigator# 56622
🇺🇸
Philadelphia, Pennsylvania, United States
Site Reference ID/Investigator# 57583
🇺🇸
Birmingham, Alabama, United States
Site Reference ID/Investigator# 55530
🇺🇸
Birmingham, Alabama, United States
Site Reference ID/Investigator# 55385
🇺🇸
Dothan, Alabama, United States
Site Reference ID/Investigator# 61042
🇺🇸
Bakersfield, California, United States
Site Reference ID/Investigator# 43651
🇺🇸
Coronado, California, United States
Site Reference ID/Investigator# 43652
🇺🇸
Costa Mesa, California, United States
Site Reference ID/Investigator# 43565
🇺🇸
San Diego, California, United States
Site Reference ID/Investigator# 59130
🇺🇸
Los Angeles, California, United States
Site Reference ID/Investigator# 43917
🇺🇸
Gainesville, Florida, United States
Site Reference ID/Investigator# 55540
🇺🇸
Macon, Georgia, United States
Site Reference ID/Investigator# 55531
🇺🇸
Wellington, Florida, United States
Site Reference ID/Investigator# 43576
🇺🇸
Indianapolis, Indiana, United States
Site Reference ID/Investigator# 44621
🇺🇸
Chicago, Illinois, United States
Site Reference ID/Investigator# 55383
🇺🇸
Bowling Green, Kentucky, United States
Site Reference ID/Investigator# 55901
🇺🇸
Baltimore, Maryland, United States
Site Reference ID/Investigator# 43587
🇺🇸
St. Paul, Minnesota, United States
Site Reference ID/Investigator# 43569
🇺🇸
Kansas City, Missouri, United States
Site Reference ID/Investigator# 44608
🇺🇸
St. Louis, Missouri, United States
Site Reference ID/Investigator# 43566
🇺🇸
Manhasset, New York, United States
Site Reference ID/Investigator# 55526
🇺🇸
Egg Harbor Township, New Jersey, United States
Site Reference ID/Investigator# 43573
🇺🇸
New York, New York, United States
Site Reference ID/Investigator# 59133
🇺🇸
Monticello, New York, United States
Site Reference ID/Investigator# 43586
🇺🇸
New York, New York, United States
Site Reference ID/Investigator# 55532
🇺🇸
Poughkeepsie, New York, United States
Site Reference ID/Investigator# 55386
🇺🇸
Rochester, New York, United States
Site Reference ID/Investigator# 55538
🇺🇸
Charlotte, North Carolina, United States
Site Reference ID/Investigator# 55522
🇺🇸
Fayetteville, North Carolina, United States
Site Reference ID/Investigator# 55533
🇺🇸
Cincinnati, Ohio, United States
Site Reference ID/Investigator# 43585
🇺🇸
Medford, Oregon, United States
Site Reference ID/Investigator# 43665
🇺🇸
Cincinnati, Ohio, United States
Site Reference ID/Investigator# 55539
🇺🇸
Portland, Oregon, United States
Site Reference ID/Investigator# 43592
🇺🇸
Germantown, Tennessee, United States
Site Reference ID/Investigator# 59132
🇺🇸
Houston, Texas, United States
Site Reference ID/Investigator# 43662
🇺🇸
Annandale, Virginia, United States
Site Reference ID/Investigator# 43666
🇺🇸
Newport News, Virginia, United States
Site Reference ID/Investigator# 43577
🇺🇸
San Antonio, Texas, United States
Site Reference ID/Investigator# 44850
🇦🇺
Adelaide, Australia
Site Reference ID/Investigator# 55387
🇺🇸
Milwaukee, Wisconsin, United States
Site Reference ID/Investigator# 44849
🇦🇺
Herston, Australia
Site Reference ID/Investigator# 44084
🇨🇦
Calgary, Canada
Site Reference ID/Investigator# 44852
🇦🇺
Kogarah, Australia
Site Reference ID/Investigator# 43905
🇨🇦
Vancouver, Canada
Site Reference ID/Investigator# 44755
🇫🇷
Clichy, France
Site Reference ID/Investigator# 58889
🇫🇷
Pessac, France
Site Reference ID/Investigator# 44754
🇫🇷
Paris, France
Site Reference ID/Investigator# 44760
🇫🇷
Vandoeuvre Les Nancy, France
Site Reference ID/Investigator# 59303
🇩🇪
Berlin, Germany
Site Reference ID/Investigator# 46103
🇩🇪
Frankfurt, Germany
Site Reference ID/Investigator# 43675
🇵🇷
San Juan, Puerto Rico
Site Reference ID/Investigator# 46485
🇪🇸
Barcelona, Spain
Site Reference ID/Investigator# 45363
🇪🇸
Barcelona, Spain
Site Reference ID/Investigator# 45668
🇪🇸
Barcelona, Spain
Site Reference ID/Investigator# 46484
🇪🇸
Madrid, Spain
Site Reference ID/Investigator# 45667
🇪🇸
Madrid, Spain
Site Reference ID/Investigator# 45671
🇪🇸
Majadahonda (Madrid), Spain
Site Reference ID/Investigator# 57545
🇬🇧
Dundee, United Kingdom
Site Reference ID/Investigator# 46583
🇪🇸
Seville, Spain
Site Reference ID/Investigator# 45405
🇪🇸
Valencia, Spain
Site Reference ID/Investigator# 58811
🇬🇧
London, United Kingdom
Site Reference ID/Investigator# 57882
🇬🇧
Nottingham, United Kingdom
Site Reference ID/Investigator# 59262
🇬🇧
London, United Kingdom
Site Reference ID/Investigator# 57547
🇬🇧
London, United Kingdom
Site Reference ID/Investigator# 57543
🇬🇧
Southampton, United Kingdom
Site Reference ID/Investigator# 43910
🇺🇸
Aurora, Colorado, United States
Site Reference ID/Investigator# 43574
🇺🇸
Seattle, Washington, United States
Site Reference ID/Investigator# 55542
🇺🇸
Statesville, North Carolina, United States
Site Reference ID/Investigator# 43572
🇺🇸
Bradenton, Florida, United States
Site Reference ID/Investigator# 44758
🇫🇷
Creteil, France
Site Reference ID/Investigator# 58922
🇩🇪
Kiel, Germany
Site Reference ID/Investigator# 44847
🇳🇿
Auckland, New Zealand
Site Reference ID/Investigator# 43672
🇵🇷
San Juan, Puerto Rico
Site Reference ID/Investigator# 55500
🇺🇸
Phoenix, Arizona, United States
Site Reference ID/Investigator# 55384
🇺🇸
Jacksonville, Florida, United States
Site Reference ID/Investigator# 43578
🇺🇸
Madison, Wisconsin, United States
Site Reference ID/Investigator# 59304
🇩🇪
Berlin, Germany
Site Reference ID/Investigator# 58886
🇫🇷
Montpellier - Cedex 5, France
Site Reference ID/Investigator# 43568
🇺🇸
Annapolis, Maryland, United States
Site Reference ID/Investigator# 43584
🇺🇸
Fort Pierce, Florida, United States
Site Reference ID/Investigator# 55382
🇺🇸
Tucson, Arizona, United States
Site Reference ID/Investigator# 43655
🇺🇸
Ann Arbor, Michigan, United States
Site Reference ID/Investigator# 58887
🇫🇷
Marseilles, France
Site Reference ID/Investigator# 55536
🇺🇸
Zephyrhills, Florida, United States
Site Reference ID/Investigator# 59124
🇺🇸
Shreveport, Louisiana, United States
Site Reference ID/Investigator# 55534
🇺🇸
Boston, Massachusetts, United States
Site Reference ID/Investigator# 46102
🇩🇪
Hannover, Germany
Site Reference ID/Investigator# 46105
🇩🇪
Wuerzburg, Germany
Site Reference ID/Investigator# 46106
🇩🇪
Hamburg, Germany
Site Reference ID/Investigator# 43913
🇺🇸
Detroit, Michigan, United States
Site Reference ID/Investigator# 43659
🇺🇸
Nashville, Tennessee, United States
Site Reference ID/Investigator# 43656
🇺🇸
Springfield, Massachusetts, United States
Site Reference ID/Investigator# 58884
🇫🇷
Lyon, France
Site Reference ID/Investigator# 43588
🇺🇸
Lutherville, Maryland, United States
Site Reference ID/Investigator# 55723
🇺🇸
Germantown, Tennessee, United States
Site Reference ID/Investigator# 44610
🇺🇸
Wellington, Florida, United States